Literature DB >> 16563872

Medical and surgical management of adenomyosis.

Cynthia Farquhar1, Ivo Brosens.   

Abstract

Adenomyosis of the uterus is a common condition amongst women in their reproductive years. It is defined as the presence of heterotopic endometrial glands and stroma in the myometrium with adjacent smooth muscle hyperplasia. The common presenting symptoms are painful and heavy periods and infertility, although many women are asymptomatic. Adenomyosis is thought to affect 1% of women and is typically diagnosed in the 4th and 5th decades of life. The aetiology is unclear, and until recently a diagnosis was made only after invasive and destructive surgery. With the advent of improved imaging of the pelvic organs, and in particular magnetic resonance imaging, the diagnosis of adenomyosis is being made more frequently. Unfortunately, because the disease has been infrequently diagnosed prior to hysterectomy, there are few well-designed studies of medical or surgical management. Management with hormonal treatment that aims to reduce the proliferation of endometrial cells is promising, but there is a paucity of well-designed studies to guide treatment. Hysterectomy or use of the levonorgestrel intrauterine system (LNG-IUS) remains the mainstay of treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16563872     DOI: 10.1016/j.bpobgyn.2006.01.012

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  24 in total

Review 1.  A systematic review with meta-analysis: the common sonographic characteristics of adenomyosis.

Authors:  Katherine Dartmouth
Journal:  Ultrasound       Date:  2014-03-25

2.  An unexpected diagnosis of adenomyosis in the subfertile woman.

Authors:  Tia Hunjan; Andrew Davidson
Journal:  BMJ Case Rep       Date:  2015-02-27

Review 3.  Interventional therapies for controlling pelvic pain: what is the evidence?

Authors:  Isabel C Green; Sarah L Cohen; Dayna Finkenzeller; Paul J Christo
Journal:  Curr Pain Headache Rep       Date:  2010-02

4.  Berberine inhibits the LPS-induced proliferation and inflammatory response of stromal cells of adenomyosis tissues mediated by the LPS/TLR4 signaling pathway.

Authors:  Li Liu; Li Chen; Caixia Jiang; Jing Guo; Yan Xie; Le Kang; Zhongping Cheng
Journal:  Exp Ther Med       Date:  2017-10-16       Impact factor: 2.447

5.  Prediction of early response to uterine arterial embolisation of adenomyosis: value of T2 signal intensity ratio of adenomyosis.

Authors:  Dae Chul Jung; Man Deuk Kim; Young Taik Oh; Jong Yun Won; Do Yun Lee
Journal:  Eur Radiol       Date:  2012-04-17       Impact factor: 5.315

Review 6.  Adenomyosis: from the sign to the diagnosis. Imaging, diagnostic pitfalls and differential diagnosis: a pictorial review.

Authors:  A L Valentini; S Speca; B Gui; G Soglia; B G Soglia; M Miccò; L Bonomo
Journal:  Radiol Med       Date:  2011-09-02       Impact factor: 3.469

7.  Can measurement of apparent diffusion coefficient before treatment predict the response to uterine artery embolization for adenomyosis?

Authors:  Yaewon Park; Man Deuk Kim; Dae Chul Jung; Shin Jae Lee; Gyoungmin Kim; Sung Il Park; Jong Yun Won; Do Yun Lee
Journal:  Eur Radiol       Date:  2014-12-07       Impact factor: 5.315

8.  Expression of focal adhesion kinase in the eutopic endometrium of women with adenomyosis varies with dysmenorrhea and pelvic pain.

Authors:  Lin Mu; Weimin Chen; Yanyan Ma; Wei Zheng
Journal:  Exp Ther Med       Date:  2015-09-09       Impact factor: 2.447

9.  Adenomyosis a variant, not a disease? Evidence from hysterectomized menopausal women in the Study of Women's Health Across the Nation (SWAN).

Authors:  Gerson Weiss; Priya Maseelall; Laura L Schott; Sarah E Brockwell; Miriam Schocken; Janet M Johnston
Journal:  Fertil Steril       Date:  2008-02-20       Impact factor: 7.329

10.  Quercetin Inhibits Adenomyosis by Attenuating Cell Proliferation, Migration and Invasion of Ectopic Endometrial Stromal Cells.

Authors:  Wenbin Xu; Yizuo Song; Kehan Li; Biyun Zhang; Xueqiong Zhu
Journal:  Drug Des Devel Ther       Date:  2020-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.